A Phase 2 interventional study of Fast-acting insulin aspart and iLet™ in Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-06-11.
Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1 — 2 open to participants now, 2 under way, none of them phase 3. Insulin Aspart · Diabetes Mellitus, Type 1.
Among the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1, this one is the 73rd largest by enrollment, is one of 7 that started in 2019, is the only one in phase 2, and was the 76th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →2 of the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1 are open now, in 2 countries. Recruiting first, the newest first:
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 7–18
Defymed · Sites in France
Ages 18+
By country, each count listing its studies:
Insulin Aspart: first FDA approval 2000 (NOVOLOG PENFILL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 3 · Phase 3 26 · Phase 4 24
First in 1989; this study’s year is marked. 7 started in 2019.
This study's enrollment of 24 is below the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 50 across the 87 interventional studies. Of the 81 that completed or were terminated, 21 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 87 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,410 studies on the registry; 107 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S: 2 open now, 5 under way, 1 of them phase 3. Of 220 finished, 33 (15%) have results posted.
Among the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, this one is the 133rd largest by enrollment of the 149 interventional ones that give a count, is one of 2 that started in 2019, is one of 8 in phase 2, and was the 204th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 1 studies by the year they started, since 1989.
2 of the studies testing Insulin Aspart in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05221359DefymedPilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes | 2026-12 |
| NCT06532461Steno Diabetes Center CopenhagenA Trial of Three- and Seven-days Insulin Infusions Set | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 226 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
The iLet™ is a new insulin pump that is programmed to work with a Continuous Glucose Monitoring (CGM) device. This is to give participants insulin automatically. The CGM device is already available for sale. The iLet™ is not yet approved for use. Fast-acting insulin aspart is a type of insulin that doctors can already prescribe for use with insulin pens, but not for use in an insulin pump. This study is to test how safe fast acting insulin aspart is when used with different insulin delivery settings in the iLet™ in people with type 1 diabetes. Participants will get fast-acting insulin aspart as participants' insulin and use the iLet™ as participants' insulin pump with a CGM device. Participants' iLet™ will be set to 2 different insulin delivery settings for 7 days on each setting. The setting participants get first is decided by chance. The study will last for about 5 to 9 weeks. Participants will have 4 visits and 1 phone contact with the study or staff.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive fast-acting insulin aspart using the iLet™ with default tmax setting (t65 = 65 minutes) in two different treatment periods in a cross-over manner. There will be 3 different cohorts with 2 treatment periods in each cohort.
Drug: Fast-acting insulin aspart · Device: iLet™
Participants will receive fast-acting insulin aspart using the iLet™ with non-default tmax setting (t50 = 50 minutes, t40 = 40 minutes or t30 = 30 minutes) in two different treatment periods in a cross-over manner. There will be 3 different cohorts with 2 treatment periods in each cohort.
Drug: Fast-acting insulin aspart · Device: iLet™
In each cohort, participants will receive fast-acting insulin aspart using the iLet™ in a cross-over manner for 14 days (7days per period). Dose modification will be handled autonomously by the iLet™ based on the CGM sensor readings and the user interaction with the iLet™ e.g. meal announcements.
The bionic pancreas including pigtail adapters, used in insulin-only configuration
Time in Low Interstitial Glucose (Defined as Below 54 mg/dL [3 mmol/L]) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentage)
Interstitial glucose: glucose measured in interstitial fluid. Time in low interstitial glucose (defined as below 54 mg/dL \[3 mmol/L\]) from initiation of treatment (day 1) to end of treatment (day 7). Time spent in low interstitial glucose is calculated as the percentage of available interstitial glucose values below the threshold.
Time frame: Day 1 to day 7
Time in Low Interstitial Glucose (Defined as Below 54 mg/dL [3 mmol/L]) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentage) - Median
Interstitial glucose: glucose measured in interstitial fluid. Time in low interstitial glucose (defined as below 54 mg/dL \[3 mmol/L\]) from initiation of treatment (day 1) to end of treatment (day 7). Time spent in low interstitial glucose is calculated as the percentage of available interstitial glucose values below the threshold.
Time frame: Day 1 to day 7
Number of Treatment Emergent Severe Hypoglycaemic Episodes
Number of treatment emergent severe hypoglycaemic episodes from initiation of treatment (day 1) to end of treatment (day 7). Treatment emergent is defined as an episode that has onset in the period from initiation of treatment to end of treatment. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. Plasma glucose (PG) concentrations may not be available during an event, but neurological recovery following the return of PG to normal is considered sufficient evidence that the event was induced by a low PG concentration.
Time frame: Day 1 to day 7
Number of Self-manageable (Able to Self-treat) Treatment Emergent Hypoglycaemic Episodes That Require Oral Carbohydrate Intervention Per Day
Mean number of self-manageable (able to self-treat) treatment emergent hypoglycaemic episodes that require oral carbohydrate intervention per day. Self-manageable (able to self-treat) hypoglycaemic episodes that require oral carbohydrate intervention per day is calculated as the sum of all hypoglycaemic episodes where the subject is able to self-treat and that require oral carbohydrate intervention divided by the actual duration of the treatment period in days. Treatment emergent is defined as an episode that has onset in the period from initiation of treatment to end of treatment.
Time frame: Day 1 to day 7
Number of Treatment Emergent Overall Hypoglycaemic Episodes Classified According to the American Diabetes Association (ADA) Definition
ADA classification of hypoglycaemia: 1. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. 2. Asymptomatic hypoglycaemia: An episode not accompanied by typical symptoms of hypoglycaemia, but with a measured PG concentration ≤3.9 mmol/L (70 mg/dL). 3. Documented symptomatic hypoglycaemia: An episode during which typical symptoms of hypoglycaemia are accompanied by a measured PG concentration ≤ 3.9 mmol/L (70 mg/dL). 4. Pseudo-hypoglycaemia: An episode during which the person with diabetes reports any of the typical symptoms of hypoglycaemia with a measured PG concentration \> 3.9 mmol/L (70 mg/dL) but approaching that level. 5. Probable symptomatic hypoglycaemia: An episode during which symptoms of hypoglycaemia are not accompanied by a PG determination but that was presumably caused by a PG concentration ≤ 3.9 mmol/L (70 mg/dL).
Time frame: Day 1 to day 7
Number of Treatment Emergent Overall Hypoglycaemic Episodes Classified According to the Novo Nordisk Classification
Overall hypoglycaemia count according to Novo Nordisk classification. Novo Nordisk classification of hypoglycaemia: 1. Severe hypoglycaemia according to the ADA classification. 2. Symptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. 3. Asymptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) without symptoms consistent with hypoglycaemia. 4. BG confirmed hypoglycaemia: The union of 2. and 3. 5. Severe or BG confirmed symptomatic hypoglycaemia: The union of 1. and 2. 6. Severe or BG confirmed hypoglycaemia: The union of 1., 2. and 3.
Time frame: Day 1 to day 7
Number of Treatment Emergent Daytime Hypoglycaemic Episodes Classified According to the American Diabetes Association (ADA) Definition
ADA classification of hypoglycaemia: 1. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. 2. Asymptomatic hypoglycaemia: An episode not accompanied by typical symptoms of hypoglycaemia, but with a measured PG concentration ≤3.9 mmol/L (70 mg/dL). 3. Documented symptomatic hypoglycaemia: An episode during which typical symptoms of hypoglycaemia are accompanied by a measured PG concentration ≤ 3.9 mmol/L (70 mg/dL). 4. Pseudo-hypoglycaemia: An episode during which the person with diabetes reports any of the typical symptoms of hypoglycaemia with a measured PG concentration \> 3.9 mmol/L (70 mg/dL) but approaching that level. 5. Probable symptomatic hypoglycaemia: An episode during which symptoms of hypoglycaemia are not accompanied by a PG determination but that was presumably caused by a PG concentration ≤ 3.9 mmol/L (70 mg/dL).
Time frame: Day 1 to day 7 (in both the treatment periods)
Number of Treatment Emergent Daytime Hypoglycaemic Episodes Classified According to the Novo Nordisk Classification
Number of daytime hypoglycaemic episodes according to Novo Nordisk classification. Novo Nordisk classification of hypoglycaemia: 1. Severe hypoglycaemia according to the ADA classification. 2. Symptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. 3. Asymptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) without symptoms consistent with hypoglycaemia. 4. BG confirmed hypoglycaemia: The union of 2. and 3. 5. Severe or BG confirmed symptomatic hypoglycaemia: The union of 1. and 2. 6. Severe or BG confirmed hypoglycaemia: The union of 1., 2. and 3.
Time frame: Day 1 to day 7
Number of Treatment Emergent Nocturnal Hypoglycaemic Episodes Classified According to the American Diabetes Association (ADA) Definition
ADA classification of hypoglycaemia: 1. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. 2. Asymptomatic hypoglycaemia: An episode not accompanied by typical symptoms of hypoglycaemia, but with a measured PG concentration ≤3.9 mmol/L (70 mg/dL). 3. Documented symptomatic hypoglycaemia: An episode during which typical symptoms of hypoglycaemia are accompanied by a measured PG concentration ≤ 3.9 mmol/L (70 mg/dL). 4. Pseudo-hypoglycaemia: An episode during which the person with diabetes reports any of the typical symptoms of hypoglycaemia with a measured PG concentration \> 3.9 mmol/L (70 mg/dL) but approaching that level. 5. Probable symptomatic hypoglycaemia: An episode during which symptoms of hypoglycaemia are not accompanied by a PG determination but that was presumably caused by a PG concentration ≤ 3.9 mmol/L (70 mg/dL).
Time frame: Day 1 to day 7
Number of Treatment Emergent Nocturnal Hypoglycaemic Episodes Classified According to the Novo Nordisk Classification
Number of nocturnal (from time 00:01-05:59 both inclusive) hypoglycaemic episodes according to Novo Nordisk classification. Novo Nordisk classification of hypoglycaemia: 1. Severe hypoglycaemia according to the ADA classification. 2. Symptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. 3. Asymptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) without symptoms consistent with hypoglycaemia. 4. BG confirmed hypoglycaemia: The union of 2. and 3. 5. Severe or BG confirmed symptomatic hypoglycaemia: The union of 1. and 2. 6. Severe or BG confirmed hypoglycaemia: The union of 1., 2. and 3.
Time frame: Day 1 to day 7 (in both the treatment periods)
Time in Interstitial Glucose Range Was Defined as 70-180 mg/dL (3.9-10 mmol/L) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentages)
Time in interstitial glucose range defined as 70-180 mg/dL (3.9-10 mmol/L) from initiation of treatment (day 1) to end of treatment (day 7). Time spent in interstitial glucose range is calculated as the percentage of available interstitial glucose values above or equal to the low threshold and below or equal to the high threshold.
Time frame: Day 1 to day 7
Mean Interstitial-glucose Level
Mean interstitial glucose level is calculated as the average of the available interstitial glucose values.
Time frame: Day 1 to day 7
Number of Treatment Emergent Adverse Events
Number of treatment emergent adverse events from initiation of treatment (day 1) to end of treatment (day 7). Treatment emergent is defined as an event that has onset in the period from initiation of treatment to end of treatment.
Time frame: Day 1 to day 7
Number of Treatment Emergent Infusion Site Reactions
Number of treatment-emergent infusion site reactions from initiation of treatment (day 1) to end of treatment (day 7). Treatment emergent is defined as an event that has onset in the period from initiation of treatment to end of treatment.
Time frame: Day 1 to day 7
Total Insulin Dose Per Day
Total insulin dose (U/kg) per day from initiation of treatment (day 1) to end of treatment (day 7). Total daily insulin dose is calculated as the sum of all insulin doses delivered by the iLet™ divided by the actual duration of the treatment period in days.
Time frame: Day 1 to day 7
The trial was conducted at one site in the United States.
| Milestone | Cohort 1: t65 First, Then t50 | Cohort 1: t50 First, Then t65 | Cohort 2: t65 First, Then t40 | Cohort 2: t40 First, Then t65 | Cohort 3: t65 First, Then t30 | Cohort 3: t30 First, Then t65 |
|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 | 4 | 4 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 |
| Milestone | Cohort 1: t65 First, Then t50 | Cohort 1: t50 First, Then t65 | Cohort 2: t65 First, Then t40 | Cohort 2: t40 First, Then t65 | Cohort 3: t65 First, Then t30 | Cohort 3: t30 First, Then t65 |
|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 | 4 | 3 |
| Completed | 4 | 4 | 4 | 3 | 4 | 3 |
| Not completed | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Unclassified | 0 | 0 | 0 | 1 | 0 | 0 |
Interstitial glucose: glucose measured in interstitial fluid. Time in low interstitial glucose (defined as below 54 mg/dL \[3 mmol/L\]) from initiation of treatment (day 1) to end of treatment (day 7). Time spent in low interstitial glucose is calculated as the percentage of available interstitial glucose values below the threshold.
| Percentage | t50 Faster Aspart Cohort 1 | t65 Faster Aspart Cohort 1 | t40 Faster Aspart Cohort 2 | t65 Faster Aspart Cohort 2 | t30 Faster Aspart Cohort 3 | t65 Faster Aspart Cohort 3 |
|---|---|---|---|---|---|---|
| Time in Low Interstitial Glucose (Defined as Below 54 mg/dL [3 mmol/L]) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentage) | 0.98 ± 0.72 | 0.89 ± 1.16 | 0.69 ± 0.50 | 0.50 ± 0.79 | 0.61 ± 0.56 | 0.37 ± 0.41 |
Interstitial glucose: glucose measured in interstitial fluid. Time in low interstitial glucose (defined as below 54 mg/dL \[3 mmol/L\]) from initiation of treatment (day 1) to end of treatment (day 7). Time spent in low interstitial glucose is calculated as the percentage of available interstitial glucose values below the threshold.
| Percentage | t50 Faster Aspart Cohort 1 | t65 Faster Aspart Cohort 1 | t40 Faster Aspart Cohort 2 | t65 Faster Aspart Cohort 2 | t30 Faster Aspart Cohort 3 | t65 Faster Aspart Cohort 3 |
|---|---|---|---|---|---|---|
| Time in Low Interstitial Glucose (Defined as Below 54 mg/dL [3 mmol/L]) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentage) - Median | 0.93 (0.2 to 2.2) | 0.42 (0.1 to 3.6) | 0.75 (0.0 to 1.4) | 0.20 (0.0 to 2.3) | 0.58 (0.0 to 1.4) | 0.29 (0.1 to 1.3) |
Number of treatment emergent severe hypoglycaemic episodes from initiation of treatment (day 1) to end of treatment (day 7). Treatment emergent is defined as an episode that has onset in the period from initiation of treatment to end of treatment. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. Plasma glucose (PG) concentrations may not be available during an event, but neurological recovery following the return of PG to normal is considered sufficient evidence that the event was induced by a low PG concentration.
| Episodes | t50 Faster Aspart Cohort 2 | t65 Faster Aspart Cohort 1 | t40 Faster Aspart Cohort 2 | t65 Faster Aspart Cohort 2 | t30 Faster Aspart Cohort 3 | t65 Faster Aspart Cohort 3 |
|---|---|---|---|---|---|---|
| Number of Treatment Emergent Severe Hypoglycaemic Episodes | 0 | 0 | 0 | 0 | 0 | 0 |
Mean number of self-manageable (able to self-treat) treatment emergent hypoglycaemic episodes that require oral carbohydrate intervention per day. Self-manageable (able to self-treat) hypoglycaemic episodes that require oral carbohydrate intervention per day is calculated as the sum of all hypoglycaemic episodes where the subject is able to self-treat and that require oral carbohydrate intervention divided by the actual duration of the treatment period in days. Treatment emergent is defined as an episode that has onset in the period from initiation of treatment to end of treatment.
| Episodes | t50 Faster Aspart Cohort 2 | t65 Faster Aspart Cohort 1 | t40 Faster Aspart Cohort 1 | t65 Faster Aspart Cohort 2 | t30 Faster Aspart Cohort 3 | t65 Faster Aspart Cohort 3 |
|---|---|---|---|---|---|---|
| Number of Self-manageable (Able to Self-treat) Treatment Emergent Hypoglycaemic Episodes That Require Oral Carbohydrate Intervention Per Day | 1.01 ± 0.44 | 0.87 ± 0.49 | 1.06 ± 0.57 | 0.68 ± 0.43 | 0.86 ± 0.55 | 0.51 ± 0.36 |
ADA classification of hypoglycaemia: 1. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. 2. Asymptomatic hypoglycaemia: An episode not accompanied by typical symptoms of hypoglycaemia, but with a measured PG concentration ≤3.9 mmol/L (70 mg/dL). 3. Documented symptomatic hypoglycaemia: An episode during which typical symptoms of hypoglycaemia are accompanied by a measured PG concentration ≤ 3.9 mmol/L (70 mg/dL). 4. Pseudo-hypoglycaemia: An episode during which the person with diabetes reports any of the typical symptoms of hypoglycaemia with a measured PG concentration \> 3.9 mmol/L (70 mg/dL) but approaching that level. 5. Probable symptomatic hypoglycaemia: An episode during which symptoms of hypoglycaemia are not accompanied by a PG determination but that was presumably caused by a PG concentration ≤ 3.9 mmol/L (70 mg/dL).
| Episodes | t65 Faster Aspart Cohort 1 | t50 Faster Aspart Cohort 1 | t65 Faster Aspart Cohort 2 | t40 Faster Aspart Cohort 2 | t65 Faster Aspart Cohort 3 | t30 Faster Aspart Cohort 3 |
|---|---|---|---|---|---|---|
| Severe hypoglycaemia | 0 | 0 | 0 | 0 | 0 | 0 |
| Documented symptomatic hypoglycaemia | 36 | 38 | 24 | 42 | 17 | 25 |
| Asymptomatic hypoglycaemia | 9 | 15 | 8 | 6 | 4 | 9 |
| Probable symptomatic hypoglycaemia | 4 | 2 | 3 | 3 | 1 | 5 |
| Pseudo-hypoglycaemia | 3 | 8 | 3 | 6 | 3 | 6 |
Overall hypoglycaemia count according to Novo Nordisk classification. Novo Nordisk classification of hypoglycaemia: 1. Severe hypoglycaemia according to the ADA classification. 2. Symptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. 3. Asymptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) without symptoms consistent with hypoglycaemia. 4. BG confirmed hypoglycaemia: The union of 2. and 3. 5. Severe or BG confirmed symptomatic hypoglycaemia: The union of 1. and 2. 6. Severe or BG confirmed hypoglycaemia: The union of 1., 2. and 3.
| Episodes | t65 Faster Aspart Cohort 1 | t50 Faster Aspart Cohort 1 | t65 Faster Aspart Cohort 2 | t40 Faster Aspart Cohort 2 | t65 Faster Aspart Cohort 3 | t30 Faster Aspart Cohort 3 |
|---|---|---|---|---|---|---|
| Severe hypoglycaemia | 0 | 0 | 0 | 0 | 0 | 0 |
| Symptomatic BG confirmed hypoglycaemia | 13 | 12 | 4 | 13 | 6 | 10 |
| Asymptomatic BG confirmed hypoglycaemia | 3 | 3 | 3 | 1 | 1 | 2 |
| BG confirmed hypoglycaemia | 16 | 15 | 7 | 14 | 7 | 12 |
| Severe or BG confirmed symptomatic hypoglycaemia | 13 | 12 | 4 | 13 | 6 | 10 |
| Severe or BG confirmed hypoglycaemia | 16 | 15 | 7 | 14 | 7 | 12 |
ADA classification of hypoglycaemia: 1. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. 2. Asymptomatic hypoglycaemia: An episode not accompanied by typical symptoms of hypoglycaemia, but with a measured PG concentration ≤3.9 mmol/L (70 mg/dL). 3. Documented symptomatic hypoglycaemia: An episode during which typical symptoms of hypoglycaemia are accompanied by a measured PG concentration ≤ 3.9 mmol/L (70 mg/dL). 4. Pseudo-hypoglycaemia: An episode during which the person with diabetes reports any of the typical symptoms of hypoglycaemia with a measured PG concentration \> 3.9 mmol/L (70 mg/dL) but approaching that level. 5. Probable symptomatic hypoglycaemia: An episode during which symptoms of hypoglycaemia are not accompanied by a PG determination but that was presumably caused by a PG concentration ≤ 3.9 mmol/L (70 mg/dL).
| Episodes | t65 Faster Aspart Cohort 1 | t50 Faster Aspart Cohort 1 | t65 Faster Aspart Cohort 2 | t40 Faster Aspart Cohort 2 | t65 Faster Aspart Cohort 3 | t30 Faster Aspart Cohort 3 |
|---|---|---|---|---|---|---|
| Severe hypoglycaemia | 0 | 0 | 0 | 0 | 0 | 0 |
| Documented symptomatic hypoglycaemia | 30 | 31 | 21 | 35 | 14 | 22 |
| Asymptomatic hypoglycaemia | 5 | 11 | 5 | 4 | 4 | 7 |
| Probable symptomatic hypoglycaemia | 3 | 2 | 3 | 2 | 0 | 4 |
| Pseudo-hypoglycaemia | 2 | 5 | 3 | 6 | 2 | 6 |
Number of daytime hypoglycaemic episodes according to Novo Nordisk classification. Novo Nordisk classification of hypoglycaemia: 1. Severe hypoglycaemia according to the ADA classification. 2. Symptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. 3. Asymptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) without symptoms consistent with hypoglycaemia. 4. BG confirmed hypoglycaemia: The union of 2. and 3. 5. Severe or BG confirmed symptomatic hypoglycaemia: The union of 1. and 2. 6. Severe or BG confirmed hypoglycaemia: The union of 1., 2. and 3.
| Episodes | t65 Faster Aspart Cohort 1 | t50 Faster Aspart Cohort 1 | t65 Faster Aspart Cohort 2 | t40 Faster Aspart Cohort 2 | t65 Faster Aspart Cohort 3 | t30 Faster Aspart Cohort 3 |
|---|---|---|---|---|---|---|
| Severe hypoglycaemia | 0 | 0 | 0 | 0 | 0 | 0 |
| Symptomatic BG confirmed hypoglycaemia | 12 | 9 | 3 | 9 | 3 | 9 |
| Asymptomatic BG confirmed hypoglycaemia | 2 | 1 | 2 | 0 | 1 | 2 |
| BG confirmed hypoglycaemia | 14 | 10 | 5 | 9 | 4 | 11 |
| Severe or BG confirmed symptomatic hypoglycaemia | 12 | 9 | 3 | 9 | 3 | 9 |
| Severe or BG confirmed hypoglycaemia | 14 | 10 | 5 | 9 | 4 | 11 |
ADA classification of hypoglycaemia: 1. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. 2. Asymptomatic hypoglycaemia: An episode not accompanied by typical symptoms of hypoglycaemia, but with a measured PG concentration ≤3.9 mmol/L (70 mg/dL). 3. Documented symptomatic hypoglycaemia: An episode during which typical symptoms of hypoglycaemia are accompanied by a measured PG concentration ≤ 3.9 mmol/L (70 mg/dL). 4. Pseudo-hypoglycaemia: An episode during which the person with diabetes reports any of the typical symptoms of hypoglycaemia with a measured PG concentration \> 3.9 mmol/L (70 mg/dL) but approaching that level. 5. Probable symptomatic hypoglycaemia: An episode during which symptoms of hypoglycaemia are not accompanied by a PG determination but that was presumably caused by a PG concentration ≤ 3.9 mmol/L (70 mg/dL).
| Episodes | t65 Faster Aspart Cohort 1 | t50 Faster Aspart Cohort 1 | t65 Faster Aspart Cohort 2 | t40 Faster Aspart Cohort 2 | t65 Faster Aspart Cohort 3 | t30 Faster Aspart Cohort 3 |
|---|---|---|---|---|---|---|
| Severe hypoglycaemia | 0 | 0 | 0 | 0 | 0 | 0 |
| Documented symptomatic hypoglycaemia | 6 | 7 | 3 | 7 | 3 | 3 |
| Asymptomatic hypoglycaemia | 4 | 4 | 3 | 2 | 0 | 2 |
| Probable symptomatic hypoglycaemia | 1 | 0 | 0 | 1 | 1 | 1 |
| Pseudo-hypoglycaemia | 1 | 3 | 0 | 0 | 1 | 0 |
Number of nocturnal (from time 00:01-05:59 both inclusive) hypoglycaemic episodes according to Novo Nordisk classification. Novo Nordisk classification of hypoglycaemia: 1. Severe hypoglycaemia according to the ADA classification. 2. Symptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. 3. Asymptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) without symptoms consistent with hypoglycaemia. 4. BG confirmed hypoglycaemia: The union of 2. and 3. 5. Severe or BG confirmed symptomatic hypoglycaemia: The union of 1. and 2. 6. Severe or BG confirmed hypoglycaemia: The union of 1., 2. and 3.
| Episodes | t65 Faster Aspart Cohort 1 | t50 Faster Aspart Cohort 1 | t65 Faster Aspart Cohort 2 | t40 Faster Aspart Cohort 2 | t65 Faster Aspart Cohort 3 | t30 Faster Aspart Cohort 3 |
|---|---|---|---|---|---|---|
| Severe hypoglycaemia | 0 | 0 | 0 | 0 | 0 | 0 |
| Symptomatic BG confirmed hypoglycaemia | 1 | 3 | 1 | 4 | 3 | 1 |
| Asymptomatic BG confirmed hypoglycaemia | 1 | 2 | 1 | 1 | 0 | 0 |
| BG confirmed hypoglycaemia | 2 | 5 | 2 | 5 | 3 | 1 |
| Severe or BG confirmed symptomatic hypoglycaemia | 1 | 3 | 1 | 4 | 3 | 1 |
| Severe or BG confirmed hypoglycaemia | 2 | 5 | 2 | 5 | 3 | 1 |
Time in interstitial glucose range defined as 70-180 mg/dL (3.9-10 mmol/L) from initiation of treatment (day 1) to end of treatment (day 7). Time spent in interstitial glucose range is calculated as the percentage of available interstitial glucose values above or equal to the low threshold and below or equal to the high threshold.
| Percentage | t50 Faster Aspart Cohort 1 | t65 Faster Aspart Cohort 1 | t40 Faster Aspart Cohort 2 | t65 Faster Aspart Cohort 2 | t30 Faster Aspart Cohort 3 | t65 Faster Aspart Cohort 3 |
|---|---|---|---|---|---|---|
| Time in Interstitial Glucose Range Was Defined as 70-180 mg/dL (3.9-10 mmol/L) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentages) | 70.87 ± 9.35 | 66.79 ± 10.39 | 73.93 ± 6.14 | 70.44 ± 8.49 | 78.32 ± 6.96 | 73.82 ± 11.79 |
Mean interstitial glucose level is calculated as the average of the available interstitial glucose values.
| mg/dL | t50 Faster Aspart Cohort 1 | t65 Faster Aspart Cohort 1 | t40 Faster Aspart Cohort 2 | t65 Faster Aspart Cohort 2 | t30 Faster Aspart Cohort 3 | t65 Faster Aspart Cohort 3 |
|---|---|---|---|---|---|---|
| Mean Interstitial-glucose Level | 150.3 ± 7.8 | 157.7 ± 11.0 | 150.1 ± 8.5 | 157.6 ± 11.5 | 144.1 ± 7.1 | 152.5 ± 11.4 |
Number of treatment emergent adverse events from initiation of treatment (day 1) to end of treatment (day 7). Treatment emergent is defined as an event that has onset in the period from initiation of treatment to end of treatment.
| Events | t50 Faster Aspart Cohort 1 | t65 Faster Aspart Cohort 1 | t40 Faster Aspart Cohort 2 | t65 Faster Aspart Cohort 2 | t30 Faster Aspart Cohort 3 | t65 Faster Aspart Cohort 3 |
|---|---|---|---|---|---|---|
| Number of Treatment Emergent Adverse Events | 2 | 2 | 2 | 0 | 0 | 1 |
Number of treatment-emergent infusion site reactions from initiation of treatment (day 1) to end of treatment (day 7). Treatment emergent is defined as an event that has onset in the period from initiation of treatment to end of treatment.
| Infusion site reaction | t50 Faster Aspart Cohort 1 | t65 Faster Aspart Cohort 1 | t40 Faster Aspart Cohort 2 | t65 Faster Aspart Cohort 2 | t30 Faster Aspart Cohort 3 | t65 Faster Aspart Cohort 3 |
|---|---|---|---|---|---|---|
| Number of Treatment Emergent Infusion Site Reactions | 0 | 0 | 0 | 0 | 0 | 1 |
Total insulin dose (U/kg) per day from initiation of treatment (day 1) to end of treatment (day 7). Total daily insulin dose is calculated as the sum of all insulin doses delivered by the iLet™ divided by the actual duration of the treatment period in days.
| U/Kg/day | t50 Faster Aspart Cohort 1 | t65 Faster Aspart Cohort 1 | t40 Faster Aspart Cohort 1 | t65 Faster Aspart Cohort 2 | t30 Faster Aspart Cohort 3 | t65 Faster Aspart Cohort 3 |
|---|---|---|---|---|---|---|
| Total Insulin Dose Per Day | 0.60 ± 0.12 | 0.63 ± 0.12 | 0.65 ± 0.13 | 0.67 ± 0.16 | 0.63 ± 0.12 | 0.64 ± 0.18 |
Collected over From the first trial-related activity (screening, day -14) after obtaining informed consent and until the follow up visit (treatment days 7 in both periiods+7 days follow-up). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| t50 Faster Aspart Cohort 1 | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| t65 Faster Aspart Cohort 1 | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| t40 Faster Aspart Cohort 2 | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| t65 Faster Aspart Cohort 2 | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| t30 Faster Aspart Cohort 3 | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| t65 Faster Aspart Cohort 3 | 0/7 (0%) | 0/7 (0%) | 1/7 (14.3%) |
| Event | t50 Faster Aspart Cohort 1 | t65 Faster Aspart Cohort 1 | t40 Faster Aspart Cohort 2 | t65 Faster Aspart Cohort 2 | t30 Faster Aspart Cohort 3 | t65 Faster Aspart Cohort 3 |
|---|---|---|---|---|---|---|
| Infusion site reactionGeneral disorders | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 1/7 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/8 | 1/8 | 0/8 | 0/8 | 0/8 | 0/7 |
| PyrexiaGeneral disorders | 0/8 | 0/8 | 1/8 | 0/8 | 0/8 | 0/7 |
| Viral upper respiratory tract infectionInfections and infestations | 1/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/7 |
| VomitingGastrointestinal disorders | 0/8 | 0/8 | 1/8 | 0/8 | 0/8 | 0/7 |
| Age, Continuous(Years) | Cohort 1 | Cohort 2 | Cohort 3 | Total |
|---|---|---|---|---|
| Mean | 45.5 ± 13.5 | 36.3 ± 14.8 | 47.1 ± 10.7 | 43.0 ± 13.4 |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Total |
|---|---|---|---|---|
| Female | 6 | 7 | 5 | 18 |
| Male | 2 | 1 | 3 | 6 |
| Race (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 7 | 8 | 8 | 23 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Feb 2019 to primary completion in May 2019, 3 months.
Results were first posted in Jun 2020, 1 year after primary completion.
Of 51 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's 3 months is below that.
Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Aspart